Evidence map›Paper›PMID 40538514›Full record

ArticleWorld journal of gastroenterology2025

Mechanisms underlying hepatocellular carcinoma progression through N6-methyladenosine modifications of long non-coding RNA.

Ning Wang, Fei-Tian Min, Wei-Bo Wen, Huan-Tian Cui

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ning WangThe First School of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming 650000, Yunnan Province, China.
Fei-Tian MinThe First School of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming 650000, Yunnan Province, China.
Wei-Bo WenThe First School of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming 650000, Yunnan Province, China.
Huan-Tian CuiThe First School of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming 650000, Yunnan Province, China. 1762316411@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a highly lethal malignancy with limited treatment options, particularly for patients with advanced stages of the disease. Sorafenib, the standard first-line therapy, faces significant challenges due to the development of drug resistance. Yu

Indexed as

AdenosineCarcinoma, HepatocellularLiver NeoplasmsRNA, Long NoncodingAnimalsAntineoplastic AgentsDisease ProgressionDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMethyltransferasesNeoplastic Stem CellsSorafenibAdenosineAntineoplastic AgentsMethyltransferasesMETTL3 protein, humanN-methyladenosineRNA, Long NoncodingSorafenibHepatocellular carcinomaLong non-coding RNA KIF9-AS1N6-methyladenosineShort stature homeobox 2Sorafenib resistanceStemness

Identifiers

PMID40538514
PMCPMC12175860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.